NAPVSIPQ, also commonly known by the acronym NAP, is an eight-amino acid neuroprotective peptide.1 It has been shown to offer cognitive protection in patients with amnesic mild cognitive impairment, which is a precursor to Alzheimer's disease.2
This peptide fragment is derived from Activity-Dependent Neuroprotective Protein (ADNP) and may stabilize microtubule breakdown, indicating a useful avenue of investigation of therapeutic strategies for Parkinson's, Alzheimer's and related diseases.3
A recent paper suggests that application of this small peptide, results in a reduction of aluminum ion neurotoxicity. It is believed that the aluminum ion-induced accumulation of β-amyloid 1–42 may cause risk of Alzheimer’s disease.4
Peptides International has recently added NAP peptide to our extensive neurological research and more specifically, to the Alzheimer’s disease product line.
Synonyms/Product Alternate Names: Davunetide; ADNP Neuropeptide Fragment; H-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-OH
(M.W. 824.94) C36H60N10O12 [11439-12-2]
I. Goezes, et al., Front Mol Neurosci., 11, 151 (2018).
I. Goezes, et al., CNS Drug Review, 11(4), 353 (2005).
S. Qurasishe, et al., Sci Rep., 6, 38224 (2016).
S. Vaisburb, et al., Sci Rep., 5, 16300 (2015).